Work

XS003, an amorphous re-formulation of nilotinib, demonstrates improved dose linearity and minimal food effect, reducing the risk of QT-prolongation at fed conditions

Year: 2025

Type: conference-abstract

Source: Blood

DOI: 10.1182/blood-2025-5547

Authors: Mikael von Euler, Charlotta Liljebris, Magnus Brisander, Per Andersson, Hans Lennernäs, Börje Darpö, Leif Stenke

Institutions: Uppsala University, Karolinska University Hospital, Karolinska Institutet

Language: English

Topic: Drug Solubulity and Delivery Systems

Subfield: Pharmaceutical Science

Field: Pharmacology, Toxicology and Pharmaceutics

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4417015854

Cites:

Cited by:

Related to: